Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$2,588 Mln
Revenue (TTM)
$247 Mln
Net Profit (TTM)
$0 Mln
ROE
-0.6 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
4.3
Industry P/E
--
EV/EBITDA
4
Div. Yield
0 %
Debt to Equity
0.2
Book Value
$5.9
EPS
$-3.3
Face value
--
Shares outstanding
125,349,476
CFO
$-167.46 Mln
EBITDA
$-833.86 Mln
Net Profit
$-834.25 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Arcus Biosciences (RCUS)
| -3.7 | 12.7 | -3.7 | 197.8 | 8.0 | -4.5 | -- |
|
BSE Sensex
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
2019
|
|---|---|---|---|---|---|---|---|
|
Arcus Biosciences (RCUS)
| 60.0 | -21.9 | -7.6 | -48.9 | 55.9 | 157.0 | -6.2 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 | 20.9 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 | 14.4 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Arcus Biosciences (RCUS)
|
23.0 | 2,588.5 | 247.0 | -353.0 | -131.6 | -63.3 | -- | 4.3 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Arcus Biosciences, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cancer therapies in the United States. The company's development product portfolio includes Casdatifan, a HIF-2a inhibitor for the treatment of kidney... cancer; Domvanalimab, an anti-TIGIT antibody, which is in Phase 2 and Phase 3 clinical trial for lung and gastrointestinal cancers; and Zimberelimab, an anti-PD-1 antibody. It also develops Quemliclustat, a small molecule inhibitor that targets the CD73 enzyme in the ATP-adenosine pathway, which is in phase 3 and phase 1/1b clinical trial for lung and pancreatic cancer. In addition, the company develops AB598, a CD39 antibody, which is in phase 1/1b clinical study for gastrointestinal cancer and AB801, an AXL inhibitor, which is in Phase 1b clinical trial for lung cancer. It has clinical collaboration with AstraZeneca for the Phase 3 PACIFIC-8 trial evaluating domvanalimab and durvalumab in Stage 3 NSCLC and for a Phase 1/1b study evaluating casdatifan and volrustomig in IO-naive patients with ccRCC and BVF Partners L.P. to support the discovery and development of compounds for the treatment of inflammatory diseases. Arcus Biosciences, Inc. was incorporated in 2015 and is based in Hayward, California. Address: 3928 Point Eden Way, Hayward, CA, United States, 94545 Read more
Co-Founder, Chairman & CEO
Dr. Terry J. Rosen Ph.D.
Co-Founder, Chairman & CEO
Dr. Terry J. Rosen Ph.D.
Headquarters
Hayward, CA
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Arcus Biosciences Inc (RCUS) is $22.96 (NYSE) as of 02-Apr-2026 19:51 EDT. Arcus Biosciences Inc (RCUS) has given a return of 7.97% in the last 3 years.
Since, TTM earnings of Arcus Biosciences Inc (RCUS) is negative, P/E ratio is not available.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2025
|
-7.25
|
4.06
|
|
2024
|
-4.82
|
2.82
|
|
2023
|
-4.67
|
3.10
|
|
2022
|
-5.62
|
2.29
|
|
2021
|
57.54
|
3.62
|
The 52-week high and low of Arcus Biosciences Inc (RCUS) are Rs 26.40 and Rs 6.50 as of 04-Apr-2026.
Arcus Biosciences Inc (RCUS) has a market capitalisation of $ 2,588 Mln as on 31-Mar-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Arcus Biosciences Inc (RCUS), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
$1.12
(
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.